Aromatic-Cationic Peptide Conjugates for Therapeutic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods face challenges in delivering therapeutic biological molecules across cell membranes due to selective permeability, limiting their effectiveness in treating various diseases and conditions.
Innovation Solution
Conjugating aromatic-cationic peptides with therapeutic biological molecules to enhance cellular uptake, using chemical or physical bonds, and employing labile linkages that can be enzymatically cleaved to release the peptides within cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic biological molecules are administered directly, then the treatment approach is simple, but the molecules cannot effectively cross cell membranes due to selective permeability
Solution Approach 1:
The patent employs cell-penetrating peptides as intermediary carriers that facilitate the transport of therapeutic biological molecules across cell membranes. The peptides act as mediators between the extracellular therapeutic molecules and the intracellular target, enabling delivery without directly modifying the therapeutic molecules themselves.
Solution Approach 2:
The invention creates composite structures by conjugating cell-penetrating peptides with therapeutic biological molecules through chemical linkers. This forms a hybrid molecule that combines the membrane-crossing capability of the peptide with the therapeutic function of the biological molecule, resolving the contradiction between simplicity and effectiveness.
2Quantity of substance
If therapeutic molecules are conjugated with aromatic-cationic peptides to enhance cellular uptake, then bioavailability improves, but the composition structure becomes more complex
Solution Approach 1:
The patent applies local quality by modifying only specific regions of the therapeutic molecule system. The cell-penetrating peptide portion is designed with specific aromatic and cationic residues at particular positions to optimize membrane interaction, while the therapeutic molecule portion retains its native structure and function. This localized optimization enhances bioavailability without requiring complete structural redesign.
Solution Approach 2:
The invention utilizes parameter changes by adjusting the chemical properties of the peptide conjugate, specifically incorporating aromatic residues (phenylalanine, tyrosine, tryptophan) and cationic residues (arginine, lysine) at optimized positions. These parameter adjustments in amino acid composition and charge distribution enhance cellular uptake while maintaining controllable structural complexity.
3Productivity
If stable conjugates are used for delivery, then delivery efficiency is high, but the therapeutic molecules cannot be released inside cells
Solution Approach 1:
The patent implements dynamics by designing conjugates with conditional stability. The peptide-molecule conjugate maintains stability during circulation and cellular uptake processes, but undergoes controlled degradation or cleavage once inside the cell. This dynamic behavior allows the system to transition from a stable delivery vehicle to a releasing mechanism, simultaneously achieving high delivery efficiency and effective intracellular release.
Solution Approach 2:
The invention applies preliminary action by pre-designing the conjugate structure with built-in release mechanisms before administration. The linker chemistry is selected to be stable under extracellular conditions but labile under intracellular conditions (such as protease-sensitive or pH-sensitive linkers). This preliminary configuration ensures that release occurs automatically upon cellular internalization without requiring additional activation steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves the bioavailability and therapeutic efficacy of therapeutic biological molecules by facilitating their entry into cells, effectively treating a wide range of diseases and conditions, including neurological disorders, mitochondrial permeability transitions, and oxidative damage.
Implementation Method 1
Conjugating aromatic-cationic peptides with therapeutic biological molecules to enhance cellular uptake
Implementation Method 2
employing labile linkages that can be enzymatically cleaved to release the peptides within cells
Data Source
AI summary
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2′,6′-Dmt-Lys-Phe-NH2.